Lantheus Holdings stock faces a new Curium review window

Published on 09/22/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lantheus Holdings stock faces a 30-day antitrust review ending October 21, 2026, after Curium refiles its merger notice. The deal is valued at USD 8 billion.

LANT, US5156731020, Illustration mit AI erstellt.

Lantheus Holdings, Inc. (ISIN US5156731020) faces a new regulatory timetable for its planned Curium acquisition after the Hart-Scott-Rodino filing was resubmitted on September 21, 2026. The new waiting period runs for 30 days and is scheduled to expire on October 21, 2026, at 11:59 p.m. Eastern Time.

Curium review gets a reset

According to StockTitan on September 21, 2026, Curium withdrew the earlier filing on September 17 and resubmitted it on September 21, starting a new 30-day HSR waiting period. The filing states that the period may end earlier or be extended if the Federal Trade Commission requests additional information.

The transaction has a reported value of USD 8 billion. According to TradingView on September 21, 2026, Lantheus still expects the merger to close in the first half of 2027. That timing is conditional on the remaining regulatory process.

Deal timing outweighs old figures

The latest filing gives investors two concrete dates: September 21, 2026, for the refiling and October 21, 2026, for the statutory waiting-period expiry. The interval is 30 days, but the October date is not necessarily the closing date because an early termination or an FTC information request could change the timetable.

The regulatory process also creates a quantified comparison with the earlier timetable. The September 21 refiling restarted the review instead of allowing the prior waiting period to continue, moving the next formal HSR checkpoint to October 21, 2026. For Lantheus, the value of the USD 8 billion transaction makes the antitrust review the central near-term event.

Stock trades on Nasdaq

StockTitan identifies Lantheus Holdings under ticker LNTH on The Nasdaq Global Market and reports market capitalization of USD 6.57 billion in its September 21, 2026 filing overview. The same source classifies the company in healthcare and the specialty and generic drug manufacturing industry.

The transaction value therefore exceeds the market capitalization figure shown in the filing overview by USD 1.43 billion, although the two amounts measure different things: the first is the reported acquisition value, while the second is the equity market value listed for Lantheus. That distinction matters when assessing the scale of the Curium deal.

Regulatory date sets the next marker

Lantheus stock remains tied to the October 21, 2026 HSR date and the expected first-half 2027 closing window. The USD 8 billion deal, the 30-day review period and the USD 6.57 billion market capitalization provide the clearest dated measures for the transaction discussion.